Common misconceptions

Common mistake
Wrong: ACh is released at the sympathetic postganglionic terminal onto target organs.
Right: Sympathetic postganglionic neurons release norepinephrine onto target organs; ACh is used at all autonomic ganglia and at parasympathetic postganglionic terminals.
Sympathetic postganglionic neurons release norepinephrine, not ACh, onto target organs. ACh is used preganglionic-to-postganglionic at every autonomic ganglion (nicotinic Nn), and also at parasympathetic postganglionic terminals (muscarinic). The confusion happens because ACh appears everywhere in the preganglionic step, but the postganglionic NT is what defines sympathetic vs. parasympathetic output to the end organ.
Common mistake
Wrong: All sympathetic postganglionic fibers release norepinephrine.
Right: Sympathetic postganglionic fibers to eccrine sweat glands and some blood vessels release ACh (cholinergic exception to the sympathetic NE rule).
Eccrine sweat glands are the classic cholinergic exception to the sympathetic-equals-NE rule. Even though these glands are anatomically sympathetically innervated, the postganglionic fiber releases ACh acting on muscarinic receptors — not NE. This is why atropine (muscarinic blocker) causes anhidrosis and why anticholinergic toxicity presents with dry skin despite being a sympathomimetic-like picture.
Common mistake
Gap: Fails to recall the enzymatic breakdown pathways and urinary metabolites of ACh and NE
ACh is broken down by acetylcholinesterase into choline and acetate at the synapse; NE is metabolized by MAO and COMT, with VMA (vanillylmandelic acid) as the major urinary metabolite.
ACh is hydrolyzed immediately at the synapse by acetylcholinesterase (AChE) into choline and acetate — there are no clinically relevant urinary metabolites to track. NE follows a different path: MAO (mitochondrial) and COMT (cytosolic/extracellular) convert NE to normetanephrine, then ultimately to VMA, which is the major urinary end-product. Knowing this pathway is the key to both pharmacology (MAO inhibitors, COMT inhibitors) and pheochromocytoma diagnosis.
Common mistake
Wrong: Serum catecholamines are the best initial test for pheochromocytoma.
Right: Plasma free metanephrines (or 24-hour urinary fractionated metanephrines/VMA) are the preferred diagnostic tests for pheochromocytoma due to higher sensitivity.
Serum catecholamines fluctuate widely because tumors secrete episodically, so a single blood draw often misses the spike. Plasma free metanephrines (and 24-hour urinary fractionated metanephrines) are preferred because tumor cells constitutively express MAO and COMT, metabolizing catecholamines into metanephrines continuously — even between secretory episodes. This gives sustained elevation and much higher diagnostic sensitivity, which is exactly why guidelines favor metanephrines over catecholamines or VMA alone.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Given a synapse in the autonomic nervous system, identify the correct neurotransmitter and receptor type — including the cholinergic exception for sympathetic innervation of eccrine sweat glands.
  2. Trace the enzymatic breakdown of ACh (via acetylcholinesterase into choline and acetate) and NE (via MAO and COMT into VMA) and identify the expected urinary metabolites.
  3. Select the most appropriate initial diagnostic lab for pheochromocytoma (plasma free metanephrines or 24-hour urinary fractionated metanephrines/VMA) and explain why serum catecholamines are inferior.

Can you avoid these mistakes?

A patient receives a drug that blocks muscarinic receptors. Which specific autonomic function would still be intact: cardiac acceleration, decreased GI motility, pupil dilation, or sweating? Explain your reasoning.
Draw the complete NE metabolic pathway from release at the synapse to final urinary excretion, naming the enzymes and intermediate metabolites at each step. Which step does phenoxybenzamine interfere with, and which step does a MAO inhibitor block?
A 35-year-old presents with episodic hypertension, headache, and diaphoresis. You suspect pheochromocytoma. You order plasma free metanephrines — they come back normal during a symptom-free period. Does this effectively rule out the diagnosis? Explain the pharmacokinetics behind your answer.
A classmate says 'all sympathetic postganglionic fibers release NE.' Give the one anatomical exception that disproves this, name the receptor subtype involved, and name a drug class that would block the response at that site.

Related topics

See how your Anki deck covers this topic.

Upload your deck for a free audit →